The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility

Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2020-11, Vol.26 (21), p.5543-5545
Hauptverfasser:	Hunter, Natasha B, Kilgore, Mark R, Davidson, Nancy E
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers, Tumor Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Female Hormones Humans Ki-67 Antigen - genetics Prognosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation. .
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-20-2451